F-1/A: Living Homeopathy Files for Nasdaq IPO, Reports Strong Interim Profit Growth

Living Homeopathy International Ltd., a leading Hong Kong-based homeopathy provider, filed for an initial public offering on the Nasdaq Capital Market, reporting a significant increase in net income for the six months ended September 30, 2025.

Summary

• Living Homeopathy International Ltd. is seeking to raise approximately $15.47 million in net proceeds from an initial public offering of 3,750,000 Class A Ordinary Shares on the Nasdaq Capital Market, at an estimated price range of $4.0 to $6.0 per share.
• The company reported a net income of $568,608 for the six months ended September 30, 2025, a substantial improvement from a net loss of $33,934 in the same period of 2024.
• Revenue for the six months ended September 30, 2025, increased by 24.3% to $5,067,468, primarily driven by a 22.8% increase in healthcare product sales and an 89.2% increase in water filters and related products.
• For the fiscal year ended March 31, 2025, total net revenue slightly decreased by 1.0% to $8,422,639, compared to $8,510,216 in 2024, mainly due to a 55.1% decrease in water filter sales, partially offset by growth in healthcare and personal care products.
• Gross profit for the six months ended September 30, 2025, rose by 25.0% to $3,818,972, with a gross margin of 75.4%. For the full year ended March 31, 2025, gross profit increased by 0.7% to $6,423,394, with a gross margin of 76.3%.
• The company is the market leader in Hong Kong's homeopathy market, holding approximately 35.8% market share in terms of product sales revenue in 2024.
• Proceeds from the offering are earmarked for advertising planning (40%), market and product development/marketing (30%), and working capital/general corporate purposes (30%).
• The company operates as a holding company incorporated in the Cayman Islands, with primary operations conducted through its wholly-owned subsidiary in Hong Kong.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While recent financial performance shows strong growth and the company holds a leading market position, significant regulatory and geopolitical risks, coupled with substantial dilution for new investors, temper the overall positive sentiment.

Positives

• Net income significantly improved to $568,608 for the six months ended September 30, 2025, from a net loss of $33,934 in the prior year period.
• Revenue for the six months ended September 30, 2025, increased by 24.3% to $5,067,468, indicating strong recent growth.
• Gross profit margins are high and slightly increasing, reaching 75.4% for the six months ended September 30, 2025, and 76.3% for the year ended March 31, 2025.
• The company holds the largest market share in the Hong Kong homeopathy market (35.8% in 2024), indicating a strong competitive position.
• Cash and cash equivalents increased by 32.0% to $3,292,625 as of September 30, 2025, from $2,494,226 as of March 31, 2025.
• Net cash generated from operating activities for the six months ended September 30, 2025, was $605,606, up from $362,130 in the prior year period.
• Management has established long-term relationships (over a decade) with the majority of its top 5 product suppliers.
• The company is diversifying its sales channels by developing an online flagship store on Tmall Global for mainland China consumers.

Negatives

• Total net revenue for the year ended March 31, 2025, decreased by 1.0% to $8,422,639, primarily due to a significant 55.1% decrease in water filters and related products sales.
• Income from operations for the year ended March 31, 2025, decreased by 36.3% to $590,250, despite an increase in net income, indicating higher non-operating income.
• The company has a substantial supplier concentration, with three suppliers accounting for 30-41% of total purchases in recent periods, and one supplier accounting for 90-96% of prepayments and accounts payable, posing supply chain risks.
• Lack of written contracts with suppliers reduces predictability and makes claiming breach of contract challenging.
• The initial public offering price is substantially higher than the net tangible book value per share, resulting in an immediate and substantial dilution of approximately $4.20 per Class A Ordinary Share for new investors.
• The company does not anticipate paying cash dividends to U.S. investors in the foreseeable future, meaning returns will rely solely on stock price appreciation.
• The company has not maintained business interruption or product liability insurance, exposing it to significant costs and business disruption from unforeseen events.

Risks

• Operating in a competitive and rapidly evolving industry, making it difficult to evaluate prospects and manage growth effectively.
• Unfavorable publicity or consumer acceptance of homeopathy products could reduce sales, as seen with past negative publicity on 'LIVING Colloidal Silver'.
• The business is heavily regulated in Hong Kong, and new markets (like mainland China via Tmall Global) may impose increasingly tightened regulatory requirements and scrutiny, affecting business growth and financial results.
• Potential product liability, false marketing, or other consumer claims could lead to substantial liabilities and regulatory penalties.
• Risk of enforcement action if the company, its employees, or mentor-mentee program participants engage in improper marketing or promotion.
• Sustainability of the mentor-mentee program relies on strict compliance with internal manuals and relevant laws, with increasing pressure from pyramid scheme regulations.
• Product recalls could incur significant and unexpected costs and damage reputation.
• The company may require substantial additional funding in the future, and there is no assurance that additional financing will be available on reasonable terms.
• Damage to brand reputation could adversely affect the business.
• Increases in labor costs in Hong Kong and non-compliance with employment laws may adversely affect operations and results.
• Failure to manage and expand supplier relationships or procure products on favorable terms could harm business and growth prospects.
• Reliance on proprietary information (trade secrets, know-how) without statutory protection in Hong Kong, making enforcement difficult.
• Accusations of infringing intellectual property rights of others and content restrictions of relevant laws.
• Failure to maintain satisfactory performance of information technology systems could disrupt business.
• Improper use, disclosure, or unauthorized access to customer data could harm reputation.
• Subject to complaints, claims, controversies, regulatory actions, arbitrations, and legal proceedings, which could have a material adverse effect.
• Financial and operating performance may be adversely affected by epidemics, natural disasters, and other catastrophes.
• Directors, officers, and Class B shareholders control a significant percentage of total voting power (88.89% after IPO), potentially limiting minority shareholder influence.
• Difficulties in protecting interests and enforcing rights through U.S. courts due to incorporation under Cayman Islands law.
• Inability to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.
• Directors are not subject to a term of office, making removal difficult without controlling shareholder consent.
• Reliance on dividends and distributions from subsidiaries, with potential limitations on their ability to make payments.
• Lack of effective internal controls over financial reporting may affect accurate reporting or fraud prevention.
• Ceasing to qualify as a foreign private issuer would incur significant additional legal, accounting, and other expenses.
• As an emerging growth company, taking advantage of certain exemptions from disclosure requirements could make performance comparisons difficult.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Board of directors may decline to register transfers of Class A Ordinary Shares in certain circumstances (though unlikely for market transactions).
• Cayman Islands economic substance requirements may affect business and operations.
• Significant oversight and discretion by the government of mainland China over Hong Kong operations, potentially leading to intervention or restrictions on fund transfers.
• Enactment of the Hong Kong National Security Law and the HKAA could impact the Hong Kong subsidiary.
• Political risks associated with conducting business in Hong Kong, including potential changes to autonomy and legal system.
• Uncertainties regarding future approvals from mainland China and Hong Kong authorities for U.S. listing and securities offerings.
• More stringent requirements from the government of mainland China for sharing auditing records could hinder ability to offer securities.
• Difficulties for overseas shareholders and/or regulators to conduct investigations or collect evidence within mainland China.
• Additional costs and procedural obstacles in enforcing foreign judgments or bringing actions in Hong Kong.
• Potential impact from changes to the currency peg system in Hong Kong.
• No public market for Class A Ordinary Shares prior to this offering, and an active trading market may not develop.
• No guarantee that future audit reports will be prepared by PCAOB-inspected auditors, potentially leading to delisting under the HFCA Act.
• Additional and more stringent criteria from Nasdaq for emerging market companies, potentially delaying or denying listing.
• Class A Ordinary Shares may be thinly traded, making it difficult to sell shares.
• Market price for Class A Ordinary Shares may be volatile, potentially unrelated to operating performance.
• If securities or industry analysts do not publish research or reports, or if recommendations change adversely, market price and trading volume could decline.
• Need for additional capital, which could result in further dilution or increased debt service obligations.
• As a foreign private issuer, disclosure obligations differ from U.S. domestic reporting companies, potentially providing less information.
• Management has no prior experience in managing and operating a public company, requiring substantial time for compliance.
• Risk of not meeting continued listing standards on the Nasdaq Capital Market if financial condition deteriorates.
• Undetermined use of proceeds from this offering, with management having considerable discretion.
• Potential classification as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences for U.S. Holders.

Future Outlook

The company plans to diversify its sales channels by developing an online flagship store on Tmall Global to sell brand-name goods to consumers in mainland China. It is also committed to promoting the regularization and standardization of the homeopathy market in Hong Kong and mainland China by working with regional institutes and medical schools. The company intends to retain all future earnings for business expansion and does not anticipate paying cash dividends to U.S. investors in the foreseeable future.

Management Comments

• "We are a Hong Kong-based homeopathy service provider committed to providing customers with access to quality homeopathy resources as alternative treatment to enhance holistic health and wellness."
• "Among all the homeopathy service providers in Hong Kong, we are ranked first by market share of approximately 35.8% in terms of homeopathic products sales revenue generated in Hong Kong in 2024, according to Frost & Sullivan."
• "We believe that we may leverage this established market share to enhance the market influence of our brand name to further attract customer attention and increase our sales."
• "We have not entered into written contracts with our suppliers, which in our commercial judgment relieves us from a binding minimum procurement amount requirement associated with written contracts with our suppliers and gives us more flexibility if we decide to replace any existing suppliers with new suppliers that can better suit our business needs."
• "We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and does not anticipate declaring or paying any dividends in the foreseeable future."

Industry Context

StockSavvy.ai notes that the Traditional and Complementary Medicine (T&CM) market in Hong Kong is experiencing robust growth, expanding from $176 million in 2019 to $309.4 million in 2023 (CAGR of 15.1%), with projections to reach $1,299.1 million by 2029 (CAGR of 25.3% from 2024-2028). This growth is driven by increasing health consciousness, cultural acceptance of traditional practices, and rising prevalence of chronic diseases. The homeopathy segment specifically grew from $16.6 million in 2019 to $20 million in 2023 (CAGR of 4.8%) and is projected to accelerate to a 12.0% CAGR from 2024-2028, reaching $42.9 million by 2029. Living Homeopathy's position as the market leader in Hong Kong (35.8% market share in 2024) places it well to capitalize on these trends, although the broader T&CM market growth drivers are not directly applicable to all of its specific product categories. The industry faces future trends of increased regulation and standardization, and growing investment in research and clinical validation, which could impact operational costs and market dynamics.

Comparison to Industry Standards

• Living Homeopathy's gross margins of 75.4% (6 months ended Sep 30, 2025) and 76.3% (year ended Mar 31, 2025) are indicative of a strong pricing strategy or efficient cost of goods, which could be competitive within the specialized homeopathy and wellness product market.
• The company's market leadership in Hong Kong with 35.8% market share in 2024, as reported by Frost & Sullivan, suggests a dominant position compared to other homeopathy service providers in that specific regional market.
• The reliance on a mentor-mentee program for sales and marketing, while potentially cost-effective, introduces regulatory compliance risks related to 'pyramid scheme' definitions, which is a unique aspect compared to traditional retail or e-commerce models of competitors.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in management's opinion, would have a material adverse effect on its business, financial condition, operating results, or cash flows.
• The company has been subject to negative publicity from time to time, including a Hong Kong Department of Health press release on February 27, 2023, regarding a case of silver poisoning allegedly involving its 'LIVING Colloidal Silver' product, leading to termination of sales for human use.

Related Party Transactions

• Sales of healthcare, personal care, and water filter products to Living Homeopathy Limited (Macau), an entity controlled by Mr. To (controlling shareholder and CEO).
• Purchases of certain healthcare products from Living Homeopathy Limited (Macau).
• Lease expenses paid to Silver Link Limited, an entity controlled by Mr. To, for office premises.
• Transfer of land and building ownership from Living Homeopathy Hong Kong to Mr. To on August 13, 2024, which also discharged associated bank borrowings of $2,162,619.
• Constructive dividends of $983,560 recorded on March 31, 2025, to LTO Holdings Ltd. (Mr. To's holding company) through reductions in amounts due from Mr. To.
• Cash dividends of $325,078 declared to LTO Holdings Ltd. during the year ended March 31, 2024.
• Amount due to Ms. Hung (a shareholder) was $1,405,631 as of September 30, 2025, and $924,241 as of March 31, 2025, which is interest-free, unsecured, and repayable on demand.

Stakeholder Impact

• **Shareholders (New Investors)**: Will experience immediate and substantial dilution of $4.20 per Class A Ordinary Share due to the IPO price being significantly higher than the net tangible book value. Returns will depend on price appreciation as no dividends are anticipated in the foreseeable future. Subject to significant regulatory and geopolitical risks related to Hong Kong/China.
• **Shareholders (Existing/Controlling)**: Mr. Ka Lun To and other Class B shareholders will retain significant voting power (88.89% after IPO), maintaining control over corporate decisions. They have received past dividends and benefits from related party transactions.
• **Employees**: The company's success depends on attracting, retaining, and motivating qualified employees, offering a dynamic work environment, competitive salaries, and performance-based bonuses. Staff costs and employee benefits increased by 11.2% for the six months ended September 30, 2025, due to increased headcount.
• **Customers**: Benefit from a diversified product portfolio and an established mentor-mentee program for education and sales. However, potential product liability claims or negative publicity could affect consumer confidence. The company is expanding sales channels to mainland China via Tmall Global.
• **Suppliers**: The company maintains long-term relationships with key suppliers, but the lack of written contracts introduces risk for both parties regarding predictability and dispute resolution. High supplier concentration means changes in these relationships could significantly impact the company.
• **Regulatory Authorities**: The company is subject to various regulations in Hong Kong (e.g., Food Safety Ordinance, Trade Descriptions Ordinance, Pyramid Schemes Prohibition Ordinance) and potentially mainland China (e.g., Cybersecurity Review Measures, Overseas Listing Trial Measures). Non-compliance could lead to fines, penalties, or business cessation.

Next Steps

• Listing Class A Ordinary Shares on the Nasdaq Capital Market under the symbol LHI, contingent upon final Nasdaq approval.
• Utilizing net proceeds for advertising planning (40%), market and product development/marketing (30%), and working capital/general corporate purposes (30%).
• Continuing to diversify sales channels, including developing the online flagship store on Tmall Global for mainland China.
• Working with regional homeopathy-related institutes, medical schools, and other organizations to promote market awareness and standardization in Hong Kong and mainland China.
• Management will continue to evaluate and monitor developments with respect to public company rules and regulations.

Key Dates

Recommendation

The company demonstrates strong recent interim financial growth and a leading market position in Hong Kong's homeopathy sector, which is a growing industry. However, the significant regulatory uncertainties and geopolitical risks associated with operating in Hong Kong and expanding into mainland China, coupled with substantial dilution for new investors in the IPO and a policy of no foreseeable dividends, present considerable headwinds. A 'hold' recommendation is appropriate for seasoned investors to monitor how the company navigates these risks and executes its growth strategies, particularly its expansion into mainland China and adherence to evolving regulatory frameworks, before committing further capital.

Keywords

Homeopathy, Healthcare Products, Personal Care Products, Water Filters, Hong Kong, IPO, Nasdaq, SEC Filing, F-1/A, Alternative Medicine, Market Share, Regulatory Risk, China Risk, Emerging Growth Company, Foreign Private Issuer, Tmall Global, Mentor-Mentee Program, Financial Performance, Dilution, Corporate Governance